Program
Amphetamine
Also written as “ADZENYS XR-ODT”, “Amphetamine Sulfate” and “Amphetamine Extended Release (ER) Tablet 20 mg”.
Its studies are mostly in Attention Deficit Disorder with Hyperactivity, led by 3 companies.
Drug pageAmphetamine: every studyAll 15 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Tris Pharma | 30 open or running | phase 4since Jul 23, 2018 | Mar 9, 2017 | none ahead |
| Azurity Pharmaceuticalsits history only | 20 open or running | phase 4since Nov 11, 2013 | Nov 11, 2013 | none ahead |
| Aytu BioPharmaits history only | 10 open or running | phase 4since Sep 5, 2025 | Sep 5, 2025 | none ahead |
Also a collaborator on its studies: Takeda.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Tris Pharma only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 9, 2017First study: phase 3 study in Attention Deficit Disorder with HyperactivityFirst studyNCT03088267 · 18 enrolled · United States
- Jul 23, 2018Phase 4 study in Attention Deficit Disorder with HyperactivityNCT03610464 · 5 enrolled · United States
- Jul 16, 2019Phase 2 study in Attention Deficit Disorder with HyperactivityNCT04027361 · 41 enrolled · United States
TargetBeta
“Dopamine transporter releasing agent; Dopamine transporter releasing agent; Dopamine transporter releasing agent; Dopamine transporter releasing agent”ChEMBL 37, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| lisdexamfetaminerule | Takeda | phase 4 | 47 |
| Bupropionrule | GlaxoSmithKline | phase 4 | 29 |
| dexmethylphenidaterule | cingulate-therapeutics | phase 4 | 14 |
Studies
All 3 Tris Pharma leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT04027361Attention Deficit Disorder with Hyperactivity · United States | 2 | Completed | Oct 15, 2021 | 41 |
| NCT03610464Attention Deficit Disorder with Hyperactivity · United States | 4 | Completed | May 23, 2018 | 5 |
| NCT03088267Attention Deficit Disorder with Hyperactivity · United States | 3 | Completed | Feb 25, 2017 | 18 |
How it is read
Names in the registry
- “ADZENYS XR-ODT”, 1 entry
- “Amphetamine Sulfate”, 1 entry
- “Amphetamine Extended Release (ER) Tablet 20 mg”, 1 entry
- “Amphetamine + SPD503”, 1 entry
- “Amphetamine”, 1 entry
Conditions, from the studies’ own filings
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.